RxDoctor Payments Data

Walter Meeker, MD

Internal Medicine · Traverse City, MINPI 1295727774

Payments from drug & device makers

$10,623in general payments, 2019–2025

Across 633 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$656
  • Boehringer Ingelheim$630
  • Corium, LLC$495
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,581100%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,623 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$74,672
Medicare patients
167
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$125,100
TrulicityDulaglutide63$93,451
JardianceEmpagliflozin70$72,651
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$63,264
FarxigaDapagliflozin Propanediol54$56,150
XareltoRivaroxaban43$56,066
MounjaroTirzepatide29$40,647
OzempicSemaglutide19$23,141
MyrbetriqMirabegron28$23,086
Xultophy 100-3.6Insulin Degludec/Liraglutide11$19,220
LinzessLinaclotide18$17,134
OxycontinOxycodone Hcl12$9,622
CreonLipase/Protease/Amylase15$8,561
Emgality PenGalcanezumab-Gnlm11$7,374
Atorvastatin Calcium402$7,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$420$134,09892 claims
PfizerEliquis$656$125,100107 claims
Boehringer IngelheimJardiance$630$72,65170 claims
GSKTrelegy Ellipta$479$63,26440 claims
AstraZenecaFarxiga$1,250$56,15054 claims
Johnson & JohnsonXarelto$219$56,06643 claims
Novo NordiskOzempic, Xultophy 100-3.6$1,038$42,36130 claims
AbbVieLinzess, Creon, Synthroid$1,412$27,30256 claims
Astellas Pharma US IncMyrbetriq$144$23,08628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →